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ABSTRACT 
Doxazosin, a selective ilpha 1 adrenoceptor antagonist recently 
approved for use in Malaysia, was assessed in six patients at-
tending an outpatient hypertensive clinic. All patients had 
essential hypertension and their blood pressure was not under 
optimum control with the current medication regimen; lack of 
optimum control being considered as a sitting diastolic pressure 
of· above 95 mmHg. Patients' baseline values for blood pressure, 
heart rate, anthropometric parameters together with haematologi-
cal, biochemical and electrocardiographic parameters were estab-
lished. Pollowing this doxazosin was added at 1 mg daily and the 
dose titrated every two weeks until optimum control was ob-
tained. Patients were followed upto 12 weeks of treatment and 
all parameters were measured again at the end of this period. 
All patients responded favourably and blood pressure was con-
trolled, ie sitting diastolic pressure below 90 mmHg, with doxa-
zosin 1-4mg daily. The systolic pressure fell from a mean of 164 
mmHg to 141 mmHg (14~) and diastolic pressure from a mean of 99 
mmHg to 86 mmHg (13~). None of the patients had any adverse ef-
fects attributable to doxazosin. Heart rate, body weight, haema-
tological and biochemical parameters and electocardiograms did 
not show any significant change with doxazosin. The above find-
ings suggest that doxazosin is an effective and well tolerated 
antihypertensive drug. However the significance of the findings 
is uncertain because of the limited numbers of patients who could 
be admitted to the study during the alloted time. 
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INTRODUCTION 
Effective blood pressure control significantly reduces morbidity 
and mortality in hypertensive patients(l). This benefit is due to 
reduction in the incidence of accelerated hypertension and hyper-
tensive complications such as cerebrovascular disease,cardiac 
failure and renal failure (1) and has been shown for patients 
whose diastolic blood pressure, prior to therapy, was over 
90 mmHg(2,3). 
Different drugs used in the treatment of hypertension have dif-
ferent adverse effects and varying metabolic consequences in 
addition to affecting the complications of hypertension differ-
ently(4).Thus there is no single drug ideally suitable for the 
whole range of hypertensive patients. Rather, the best drug needs 
to be identified according to the needs of the patient, taking 
into account any metabolic derangements and complications that 
may exist.The recommended first choice antihypertensive drugs 
have evolved with many changes during the past two decades.Vaso-
dilator alpha blockers (eg. doxazosin) currently occupy the slot 
of first choice drugs, together with angiotensin converting 
enzyme inhibitors and calcium channel blockers{4). 
Doxazosin is a newer alpha 1 adrenoceptor antagonist. This group 
of drugs selectively block post synaptic alpha 1 adrenoceptors, 
resulting in decreased contraction of smooth muscle cells. This 
effect causes arteriolar dilatation and also venodilatation. The 
arteriolar dilatation is the major contributor to the antihyper-
tensive effect of doxazosin. 
Doxazosin was recently approved for use as an antihypertensive in 
Malaysia and no data is available regarding its use in hyperten-
sion in this country. 
METHODS 
Six hypertensive patients - five female and one male - were in-
cluded in the trial during the allotted time period. 
Patient selection - Patients diagnosed as having essential hyper-
tension, whose blood pressure was not adequately controlled with 
their current therapy were included in the trial. For the purpos-
es of the trial, inadequate control of hypertension was taken as 
a sitting diastolic pressure of 95 mmHg or above. Those with a 
sitting diastolic pressure of above 115 mmHg were considered to 
have severe hypertension and were excluded.Patients whose current 
medication included an alpha blocking drug were also excluded. 
Written consent was obtained from the patients included in the 
trial and they were allowed to continue the medication they were 
currently receiv~ng. Other exclusion criteria were documented 
hypertension related acute illness in the three months prior to 
screening. 
Trial design - The study period for each patient consisted of a 
two-week baseline period, an eight-week treatment titration 
period and a four-week maintenence period. Patients were seen at 
weekly intervals during the baseline period and at two week 
intervals thereafter. Patients who demonstrated a sustained 
diastolic hypertension of 95- 115 mmHg during the baseline 
period proceeded to the treatment phase. 
Treatment commenced with the addition of doxazosin lmg daily to 
the patient's current medication regimen. The dose of doxazosin 
was adjusted by doubling the dose at two week intervals until 
diastolic blood pressure was below 95 mmHg, or a maximum dose of 
8mg daily was administered.Once the optimum dose of doxazosin was 
achieved, patients continued with that optimum dose until the 
end of the trial. 
Blood pressure was recorded after the patient had been sitting at 
rest for at least 5 minutes. Two measurements were taken at two 
minute intervals and the mean of the two readings was considered 
to be the true blood pressure. Heart rate was also recorded on 
two occasions at an interval of two minutes and the mean calcu-
lated.Diastolic blood pressure was measured at disappearance of 
Korotokoff's sounds 
Height and weight were recorded at the screening visit and weight 
monitored at each visit. 
Some haematological and biochemical parameters and electrocardi-
ography were performed at the commencement of treatment and at 
the erid of the trial. The parameters measured were haemoglobin, 
haematocrit, total white cell count, platelet count,total biliru-
bin, total serum protein and serum albumin, serum aspartate 
transaminase, serum alanine transaminase, serum alkaline phospha-
tase, serum sodium and potassium,blood urea, serum creatinine, 
fasting blood glucose, fasting serum total cholesterol and tri-
glycerides. 
Baseline values of blood pressure, heart rate, body weight and 
haematological and biochemical parameters were compared with the 
end-of-trial values and analysed statistically by means of paired 
't' tests. 
RESULTS 
Six patients were admitted to the study and all six completed the 
period of therapy with doxazosin. 
Their ages ranged from 35 years to 64 years with a mean of 53,2 
years. The mean weight at start of therapy was 59.4 kg and the 
mean height 152cm. duration of hypertension in these patients 
ranged from 5 years 20 years with a mean of 12.5 years (Table 1). 
Range .. Mean ±S.D. 
AGE(years) 35-64 53.2 ±11.0 
BASELINE WEIGHT(Kg) 46-70.5 59.4 ± 10.3 
HEIGHT (em) 148 -162 152± 5.2 
DURATION OF HYPERTENSION (years) 5-20 12.5 ± 5.4 
Table 1 - Age, weight on starting therapy, height and duration of 
hypertension of subjects 
Four out of the six patients were on one other antihypertensive 
drug and two were on two other antihypertensives. The two latter 
patients were also receiving lipid lowering agents and one of 
them aspirin (Table 2). Table 3 lists the concomitant drugs taken 
by the patients. 
Number of other concomitant Number of patients 
antihypertensive drugs 
1 4 
2 2 
Table 2 - Number of concomitant antihypertensive medication 
Concomitant drugs Number of patients 
• Enalapril 3 
Quinapril 1 
Indapamide 1 
Nifedipine 1 
Metoprolol 1 
Atenolol 1 
Cholestyramine 1 
Gemfibrozil 1 
.. Aspirin 1 
Table 3 - List of concomitant medication 
All patients who entered the study completed the period of drug 
therapy and none of them showed any adverse effects (Table~). 
Total Percentage 
' 
I 
Completed trial 6 100% 
Adverse effects Nil 0% 
Table ~ - Completion rate and rate of adverse effects 
At the end of the titration period of drug therapy, four patients 
were on lmg doxazosin daily,one on 2mg daily and the other on ~mg 
daily (Table 5). 
Daily dose of doxazosin Number of patients Percentage 
1mg 4 66.6% 
2mg 1 16.7% 
4mg 1 16.7% 
. 
Table 5 - Dose of doxazosin at the end of trial 
• 
. ~ 
The mean systolic and diastolic blood pressures at 2nd week of 
baseline (at the commencement of doxazosin therapy) were 16~ mmHg 
and 99 mmHg respectively. The mean values at the end of the 
study were 141 mmHg for systolic and 86 mmHg for diastolic. There 
was a significant difference between the blood pressures both 
systolic and diastolic, with the values at end of trial being 
lower (P< 0.05 for systolic pressure and p< 0.001 for diastolic) 
Figure 1 shows the pattern of change, for the duration of the 
study. 
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Fig 1 - Effect of doxazosin on blood pressure (sitting) 
The mean heart rate at baseline was 82/min which was not signifi-
cantly different from the mean value of 75/min at the end of the· 
study. (Fig 2). 
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Fig 2. Effect of doxazosin on heart rate 
The mean baseline weight was 59.4kg. The weight tended to in-
crease marginally during the period of doxazosin therapy. Howev-
er, at no time during the study was the weight significantly 
higher than at baseline (Fig 3). 
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Fig 3- Effect of doxazosin on weight 
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The comparison of haematological and biochemical parameters at 
baseline and end of study is shown in Table 6. In none of the 
parameters was there a significant change after doxazosin thera-
py. 
PARAMETER. BASELINE END-OF-TRIAL 
-Haemoglobin (g/dl) 12.9 12.2 
Haematocrit (%) 40.1 37.3 
Total white cells (1,000/mm3) 6.9 6.4 
Platelet count (1 ,OOO/mm3) 255.2 269~8 
Serum. bilirubin (micromol/L) 10.3 9.8 
Serum total protein (gtL) 76.0 74.5 
Serum albumin (giL) 42.5 42.3 
Aspartate transaminase (lUlL) 28.1 21.8 
Alanine transaminase (IU IL) 34.5 23.7 
Alkaline phosphatase (lUlL) 73.8 69.0 
~Blood urea (mmol/L) 4.7 5.4 
Seum cre3;tinine (rnicromol/L) 97.0 99.5 
Serum urate (micromol/L) 395.0 388.8 
Serum sodium (mmol/L) 141.3 141.3 
Serum potassium (mmol!L) 3.7 3.9 
Fasting blood glucose (mmoVL) 5.3 4.8 
Fasting total cholesterol (mmol/L) 6.3 6.7 
Fasting serum triglycerides (mmol/L) 2.2 1.4 
Table 6 - Haematological and biochemical parameters at baseline 
and at end of study. 
One of the six patients had electrocardiographic evidence of left 
ventricular hypertrophy while the other had normal electrocardio-
grams. None of the patients showed a change in the ECG findings 
at the end of the study. 
DISCUSSION 
Several studies carried out in the western countries have demon-
strated the efficay of doxazosin in the treatment of mild to 
moderate hypertension (5,6,7). It has been compared with many 
other first choice antihypertensive drugs with regard to its 
blood pressure lowering effect and also the effect on various 
biochemical parameters. Such antihypertensive drugs include beta 
adrenoceptor blockers(8,9,10),angiotensin converting enzyme 
inhibitors (11) and calcium channel blockers (12). Doxazosin has 
also been used together with the above drugs in the treatment of 
hypertension with good effects. 
The aim of this study was to assess the antihypertensive efficacy 
and tolerance of doxazosin in mild to moderate hypertension in 
the Malaysian population.The study also sought to assess the 
suitability of doxazosin as one component of a multiple drug 
regimen in hypertension. 
In patients who had been diagnosed as having essential hyperten-
sion and who were on a drug regimen which did not successfully 
control the blood pressure, addition of doxazosin to the regimen 
effectively lowered the blood pressure to satisfactory levels. 
For the purposes of this study, a sitting diastolic pressure of 
less than 90 mm Hg was considered to be satisfactory. Most pa-
tients responded to the addition of doxazosin in a low dose - 1~ 
2mg daily. This is in comparison to the recommended maximum daily 
dose of 16mg. Only one patient needed a relatively higher dose of 
4mg daily for effective blood pressure control. This demonstrates 
that doxazosin not. only is an effective antihypertensive but also 
is an ideal drug to be used in a multiple drug regimen becuase it 
does not seem to loose its own efficacy or lower that of the 
other drugs when used in combination with them. 
None of the patients suffered any adverse effects with the addi-
tion of doxazosin. The heart rate and the body wieght were not 
adversely affected. In fact the heart rate showed a gradual 
decrease with dixazosin although it was not statistically signif-
icant.The absence of a rise in heart rate is a desired property 
of any vasodilator antihypertensive drug. 
All biochemical and haematological parameters remained stable. 
This is in keeping with the results of many previous studies done 
with doxazosin. There was no significant change in serum cholest-
erol and triglycerides although some previous studies have shown 
a beneficial effect on blood lipids(5,6). There was, however, a 
downward trend in serum triglycerides. 
The one patient with electrocardiographic evidence of left ven-
tricular hypertrophy did not show any signs of regression of 
hypertrophy over the duration of the study. This is to be expect-
ed as the duration of the study was too short to observe any 
possible reversal of structural changes in the heart. 
. . ~ 
In conclusion doxazosin is seen to be an effective drug in mild 
to moderate hypertension. It is well tolerated and can be used 
together with the other commonly used first line antihypertensive 
drugs without loss of efficacy of any of the drugs involved. This 
study failed to demonstrate the lipid lowering effect of doxazo-
sin shown in previous studies. Doxazosin does not seem to ad 
versely affect any haematological or biochemical parameter . 
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